Tag Archives: EXEL

Exelixis (EXEL) Receives a Buy from William Blair

In a report released yesterday, Andy Hsieh from William Blair reiterated a Buy rating on Exelixis (EXEL – Research Report). The company’s shares closed last Monday at $24.14. According to TipRanks.com, Hsieh is a 5-star analyst with an average return

The EVP & CFO of Exelixis is Exercising Options

Yesterday it was reported that the EVP & CFO of Exelixis (EXEL – Research Report), Christopher Senner, exercised options to sell 100,000 EXEL shares at $3.66 a share, for a total transaction value of $2.58M. Following Christopher Senner’s last EXEL

BMO Capital Maintains Their Hold Rating on Exelixis (EXEL)

BMO Capital analyst George Farmer maintained a Hold rating on Exelixis (EXEL – Research Report) today and set a price target of $27.00. The company’s shares closed last Wednesday at $26.55, close to its 52-week high of $27.66. According to

Needham Believes Exelixis (NASDAQ: EXEL) Still Has Room to Grow

Needham analyst Chad Messer assigned a Buy rating to Exelixis (EXEL – Research Report) today and set a price target of $33.00. The company’s shares closed last Wednesday at $26.45, close to its 52-week high of $27.66. According to TipRanks.com,

Exelixis (EXEL) Receives a Buy from Barclays

In a report released yesterday, Peter Lawson from Barclays maintained a Buy rating on Exelixis (EXEL – Research Report), with a price target of $30.00. The company’s shares closed last Monday at $23.58, close to its 52-week high of $24.90.

Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL) and Nucana (NASDAQ: NCNA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Exelixis (EXEL – Research Report) and Nucana (NCNA – Research Report) with bullish sentiments. Exelixis (EXEL) William Blair analyst Andy Hsieh reiterated